Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Poultry and Zoonotic Diseases
4.2.2 Widened Focus on Food Safety
4.3 Market Restraints
4.3.1 Use of Counterfeit Medicine
4.3.2 Increasing Costs of Animal Testing and Veterinary Services
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Disease
5.1.1 Bronchitis
5.1.2 Avian Influenza
5.1.3 Newcastle disease
5.1.4 Marek’s Disease
5.1.5 Others
5.2 By Technology
5.2.1 Recombinant Vaccines
5.2.2 Inactivated Vaccines
5.2.3 Live Attenuated Vaccines (LAV)
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biovac
6.1.2 Boehringer Ingelheim International GmbH
6.1.3 Ceva Sant? Animale
6.1.4 Dechra Pharmaceuticals PLC
6.1.5 Elanco
6.1.6 Hester Biosciences Limited
6.1.7 Merck & Co., Inc.
6.1.8 Phibro Animal Health Corporation
6.1.9 Venky’s Limited
6.1.10 Zoetis Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS